Muscular dystrophy gene therapy - Asklepios BioPharmaceutical

Drug Profile

Muscular dystrophy gene therapy - Asklepios BioPharmaceutical

Alternative Names: Biostrophin; rAAV2.5-CMV-minidystrophin (d3990)

Latest Information Update: 19 Apr 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Asklepios BioPharmaceutical
  • Class Gene therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Duchenne muscular dystrophy

Most Recent Events

  • 07 Oct 2010 Adverse events data from a phase I trial in Duchenne muscular dystrophy released by AskBio
  • 10 Oct 2006 Asklepios has entered into a cross-agreement with GSK to develop and commercialise gene therapy treatments for a variety of indications, including muscular dystrophy
  • 29 Mar 2006 Phase-I clinical trials in Duchenne muscular dystrophy in USA (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top